Introduction
Tuberculosis (TB) is a well known chronic respiratory disease caused by the pathogenic bacterium Mycobacterium tuberculosis (Mtb). Currently, Mtb infects one-third of the world's population and approximately two million deaths occur annually (World Health Organization, 2003) . Despite the existence of multiple antimycobacterial chemotherapies, drug-resistant strains often appear owing to noncompliance with the recommended regimens. Under these circumstances, the Mtb structural genomic consortium was formed in 2000 (http://www.doe-mbi.ucla.edu/TB) with the goal of providing a structural basis for the development of novel effective therapeutics for tuberculosis (Goulding et al., 2002; Smith & Sacchettini, 2003; Terwilliger et al., 2003) . The complete genome of the best-characterized strain of Mtb, H37Rv, has been sequenced and many of the open reading frames for its proteins have been annotated (Cole et al., 1997; Camus et al., 2002) .
As members of the Mtb structural genomics consortium, we have conducted molecular cloning and preliminary X-ray analysis on the arginine repressor protein (Rv1657). Presumably, this protein acts a molecular sensor of the intracellular arginine concentration. In response to the binding of arginine, Rv1657 binds to the corresponding DNA operator site and inhibits the transcription of the operon containing most of the arginine-biosynthetic enzymes. Thus, Rv1657 regulates arginine biosynthesis in Mtb via a feedbackinhibition mechanism. The C-terminal domain of Rv1657 is responsible for the binding of arginine and for the oligomerization of the protein.
Experimental methods

Cloning, expression and purification
The entire genome of the H37Rv strain was cloned into a bacterial artificial chromosome (BAC) library at L'Institut Pasteur (Brosch et al., 1998; Gordon et al., 1999) . This library was used as the template to amplify the Rv1657 protein by PCR. Primers were designed for directional cloning of inserts into the Gateway cloning system (Invitrogen). The primer sequences were Rv1657F (5 0 -GGGACAA-GTTTGTACAAAAAAGCAGGCTCCGAAAACCTGTATTTTC-AGGGATGAGCCGCGCCAAGGCCGCGC-3 0 ) and Rv1657R (5 0 -GGGACCACTTTGTACAAGAAAGCTGGGTCTTACCGAAGG-TTCTCGAACATGCCGGCC-3 0 ). The open reading frame encoding residues 1-170 of Rv1657 was cloned into an expression plasmid with an amino-terminal glutathione-S-transferase (GST) fusion partner (pDEST-15, Invitrogen). The expression plasmid was confirmed by DNA-sequence analysis (DNA core facility, Department of Biochemistry, University of Alberta, Canada).
GST-Rv1657 was expressed in Escherichia coli BL21(DE3) pLysS cells (Novagen). Incubation of the transformed cells at 310 K was continued until the OD 600 nm reached 0.8-1.0. Subsequently, the temperature was shifted to 295 K and the medium was induced by adding isopropyl -d-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. After overnight incubation, the cells were harvested by centrifugation at 2150g for 15 min. Bacterial pellets were resuspended in phosphate-buffered saline (PBS) containing Complete protease inhibitor (Roche) and 10 mg ml À1 hen egg-white lysozyme (Sigma). For purification, the cells were lysed by freezethaw and then subjected to ultrasonication in the resuspension buffer. The lysate was cleared by centrifugation (30 min, 20 000g) and the supernatant was loaded onto a 5 ml GSTrap glutathione Sepharose column (GE Healthcare) pre-equilibrated with PBS. The GST-Rv1657 fusion protein was competitively eluted from the column with 10 mM reduced glutathione (Sigma) in 50 mM Tris-HCl pH 8.0, 2 mM DTT and 0.02% NaN 3 . The GST tag and the N-terminal recombination site were removed by proteolytic cleavage using recombinant tobacco etch virus protease (rTEV, Invitrogen). The site recognized by rTEV protease is encoded in the forward primer (italicized in the sequence given) and leaves a single glycine residue in the P1 0 position following complete proteolysis. After dialysis against PBS, the cleaved protein mixture was once again loaded onto a GSTrap column and the flowthrough fractions containing Rv1657 were dialyzed against 10 mM Tris-HCl pH 7.4 and 100 mM NaCl. The resulting solution was concentrated using an Amicon Ultra (5 kDa cutoff; Millipore). The final protein concentration reached a maximum of 12 mg ml À1 . The whole process of purification was performed at 277 K and the result of each step was monitored by 16% SDS-PAGE (Fig. 1) .
Crystallization
The initial screening of crystallization conditions for native fulllength Rv1657 was performed at 295 K using the sitting-drop vapourdiffusion technique in 96-well Intelli-plates (Hampton Research). Crystal Screens I and II and the Index Screen (Hampton Research) were applied using equal volumes (0.5 ml) of protein and precipitating solutions. Over two months, initial crystals were obtained from a variety of conditions. After optimization of the best screening conditions, X-ray diffraction-quality crystals were grown in hanging drops in 24-well VDX plates (Hampton Research) containing 1 ml protein solution at 10 mg ml À1 and 0.5 ml precipitating solution and the drops were equilibrated against 1 ml precipitating solution (20% PEG 10 000, 0.1 M HEPES pH 7.5). Crystals grew to dimensions of 100 Â 100 Â 50 mm over two months.
SDS-PAGE analysis of the crystals suggested that cleavage occurred during the crystallization process (Fig. 2) . In order to identify the cleavage site, ClustalW (Thompson et al., 1994) was used to perform sequence alignment (Fig. 3) between Rv1657 and three other ArgR proteins of known structure: those from Bacillus stearothermophilus (PDB code 1b4a; 31% identity; Ni et al., 1999) 20% SDS-PAGE analysis of the cleavage during crystallization. Lane 1, protein molecular-weight standards (kDa); lane 2, dissolved crystals that had been grown at 295 K for two months; lane 3, protein solution corresponding to that in crystallization drops stored at 277 K for two months; lane 4, a second Rv1657 preparation containing full-length protein also stored at 277 K for two months. The sample in lane 4 is overloaded and appears to be greater than 19.4 kDa; however, the molecular weight of this sample was shown to be 17 456.7 Da by mass spectrometry. Sunnerhagen et al., 1997; Van Duyne et al., 1996) . By comparing the sequences and known structures, we predicted Rv1657 to potentially be separated into two domains by virtue of a long linker containing residues 81-91. To confirm the content of the crystals, they were analyzed by MALDI-TOF mass spectrometry (Institute of Biomolecular Design, University of Alberta, Canada) and found to be composed of a single 8129.8 Da molecule. The expected molecular weight for Gly92-Arg170, 8130.24 Da, corresponds well to the measured value, which suggests that it is this domain of the protein that is most likely to be present in our crystals.
Data collection
Crystals for synchrotron data collection were first rinsed in cryoprotectant (25% glycerol in mother liquor) and then flash-cooled in liquid nitrogen. Native data sets were collected on beamline 7-1 at the Stanford Synchrotron Radiation Laboratory (SSRL) and on beamline 8.3.1 at the Advanced Light Source (ALS) at the Lawrence Berkeley National Laboratory. Raw data were reduced, integrated and scaled using the HKL-2000 program suite (Otwinowski & Minor, 1997) .
Results
Native data sets were collected from Rv1657 C-terminal domain crystals (Fig. 4) . Crystallographic statistics of the native data are summarized in Table 1 . According to the measured molecular weight of the Rv1657 C-terminal domain, 8129.8 Da, the Matthews coefficient (Matthews, 1968 ) is calculated to be 2.89 Å 3 Da À1 and the solvent content is 57.48%. The result assumes the presence of six molecules of the C-terminal domain of Rv1657 per asymmetric unit, in agreement with existing biological evidence that a hexamer is the active biological unit (Charlier et al., 1992) . The hexamer constitutes the asymmetric unit in the arginine repressor structures determined
